Table 2. CAs used by the participants.
Class | CA | Number of Patients (%) |
DHP | Amlodipine | 39 (45.9%) |
DHP | Felodipine | 13 (15.3%) |
DHP | Lercanidipine | 12 (14.1%) |
Non-DHP | Diltiazem | 10 (11.8%) |
DHP | Nifedipine | 8 (9.4%) |
Non-DHP | Verapamil | 1 (1.2%) |
Mixed | Amlodipine/Diltiazem | 1 (1.2%) |
Mixed | Felodipine/Verapamil | 1 (1.2%) |